ASCO 2026 | COWBOY trial: optimal sequencing of BRAF/MEK inhibition and immunotherapy in BRAF-mutated melanoma
Kalijn Bol, MD, Radboud University Medical Center, Nijmegen, Netherlands, explores the optimal sequencing of BRAF/MEK inhibition and immunotherapy in patients with BRAF mutated melanoma. Unfavorable results from the COWBOY (NCT02968303), SECOMBIT (NCT02631447) and EBIN (NCT03235245) trials of induction BRAF/MEK inhibition prior to immunotherapy suggests that this treatment sequence will not benefit patients, however Dr Bol highlights that in patients with higher tumor load based on LDH, BRAF/MEK inhibition may have been required for a longer period than the COWBOY trial examined to provide benefit. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
